Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fresenius SE operates as a diversified healthcare conglomerate with four primary divisions: Fresenius Medical Care (dialysis services and products, ~40% of revenue), Fresenius Kabi (generic IV drugs and clinical nutrition, ~30%), Fresenius Helios (hospital operations primarily in Germany and Spain, ~25%), and Fresenius Vamed (healthcare facility management). The company serves over 300,000 dialysis patients globally and operates 86 hospitals across Europe, generating approximately 70% of revenue from Europe and 20% from North America.
Fresenius generates revenue through three distinct models: (1) Dialysis operates on a per-treatment reimbursement model with government payers (Medicare, statutory health insurance) and private insurers, creating predictable recurring revenue with 95%+ patient retention; (2) Kabi sells commodity-like generic injectables where scale manufacturing and regulatory expertise drive 15-20% EBITDA margins; (3) Helios earns per-case reimbursement from German DRG system and Spanish public/private insurance, with profitability tied to case mix optimization and bed utilization rates (typically 75-80%). Pricing power is limited by government reimbursement rate negotiations, but volume growth comes from aging demographics driving dialysis prevalence (8-10% annual growth in ESRD patients) and hospital consolidation opportunities.
Medicare reimbursement rate changes for dialysis (ESRD Prospective Payment System updates) - each 1% rate change impacts Medical Care EBIT by ~$50-60M annually
Fresenius Medical Care operational turnaround progress - cost reduction targets of €500M by 2025, clinic closure/consolidation decisions, and care coordinator staffing efficiency
German hospital reimbursement reforms (DRG rate adjustments and structural reforms like Hospital Transparency Act) affecting Helios profitability
Generic drug pricing erosion in Kabi segment - biosimilar launch timelines and competitive intensity in key molecules like pegfilgrastim and rituximab
Currency translation effects - EUR/USD movements impact reported results given 20% USD revenue exposure and translation of Medical Care earnings
Medicare reimbursement pressure - CMS targeting dialysis rate reductions through value-based care models and bundled payment expansion, with potential 2-4% annual rate headwinds through 2030
German hospital sector structural reform - government proposals for hospital capacity reduction and minimum volume requirements could force closure of smaller Helios facilities or require significant restructuring investments
Biosimilar competition intensification in Kabi - patent cliffs on key reference biologics accelerating generic competition with 30-50% price erosion typical within 2 years of biosimilar entry
Home dialysis and wearable artificial kidney technology development - potential long-term disruption to in-center dialysis model, though commercial viability remains 5-10+ years away
DaVita consolidation in US dialysis market creating pricing pressure and talent competition - two-player oligopoly dynamics with 70% combined market share
Private equity hospital consolidation in Spain (Quirónsalud faces competition from Vithas, HM Hospitales) compressing margins through physician recruitment wars and facility arms race
Indian and Chinese generic manufacturers (Dr. Reddy's, Aurobindo, Fosun) expanding European IV generic capacity with 20-30% cost advantages threatening Kabi market share
Elevated leverage at 3.2-3.5x net debt/EBITDA following Medical Care restructuring costs - limits M&A flexibility and creates refinancing risk if EBITDA deteriorates
Pension obligations of €2-3B (primarily German defined benefit plans) sensitive to discount rate assumptions - 50bp rate decline increases liabilities by €200-300M
Contingent liabilities from ongoing US Department of Justice investigation into Medical Care billing practices - potential settlement could reach €500M-1B based on historical precedents
low - Healthcare services demonstrate defensive characteristics with dialysis representing non-discretionary life-sustaining treatment (demand inelastic to GDP). Hospital volumes show modest cyclicality through elective procedure deferrals during recessions (10-15% of Helios revenue), but emergency and chronic care admissions remain stable. Kabi generic drug demand is largely acyclical. Aging demographics in core European markets (Germany 65+ population growing 2% annually) provide structural tailwind independent of economic cycles.
Rising rates create moderate headwinds through two channels: (1) Higher financing costs on €15-18B gross debt (mix of fixed and floating rate, weighted average maturity 5-7 years) - each 100bp rate increase impacts annual interest expense by €30-50M on floating portions; (2) Valuation multiple compression as healthcare stocks trade at premium P/E ratios (18-22x) that contract when risk-free rates rise, making dividend yields less attractive. Partially offset by ability to pass through some cost inflation in contract negotiations with 12-24 month lag.
Moderate exposure through hospital bad debt provisions (2-3% of Helios revenue) which increase during recessions as uninsured/underinsured patient volumes rise, though less severe in European universal healthcare systems versus US. Dialysis has minimal credit risk with 85% government payer mix. Kabi operates on net 60-90 day payment terms with hospital customers, creating working capital sensitivity to healthcare system payment delays during fiscal stress.
value - Stock trades at 12-14x forward P/E versus healthcare sector average of 18-20x, attracting deep value investors betting on Medical Care turnaround and multiple re-rating. Dividend yield of 2.5-3.0% appeals to European income investors, though payout suspended 2024-2025 during restructuring. Turnaround complexity and regulatory overhang deter growth investors. Recent 180% EPS growth reflects recovery from depressed 2024 base rather than sustainable expansion.
moderate - Historical beta of 0.8-1.0 to European healthcare indices. Stock experiences elevated volatility around quarterly earnings (±8-12% moves) due to Medical Care restructuring uncertainty and reimbursement rate announcements. Currency translation creates additional volatility for USD-based investors. Less volatile than pure-play dialysis competitors due to diversification across four segments.
